Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population

Journal of Managed Care Pharmacy

Volumn 12, Issue 1, 2006, Pages 33-42

  Heaton, Pamela C ^a   Guo, Jeff J ^a   Hornung, Richard W ^c   Johnston, Joseph A ^d   Jang, Raymond ^a   Moomaw, Charles J ^c   Cluxton Jr , Robert J ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Asthma; Cost benefit analysis; Effectiveness; Leukotriene modifiers; Medicaid

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MONTELUKAST; ORCIPRENALINE; PREDNISONE; SALBUTAMOL; STEROID; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST; ZILEUTON; LEUKOTRIENE;

ADULT; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG USE; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; SCORING SYSTEM; COMPARATIVE STUDY; ECONOMICS; LONGITUDINAL STUDY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ADULT; ASTHMA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LEUKOTRIENES; LONGITUDINAL STUDIES; MALE; MEDICAID; MIDDLE AGED; OHIO; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33646555119     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.1.33     Document Type: Article

References (57)

1. National Center for Health Statistics APHCUaM2. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm. Accessed May 10, 2005.
2. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
3. Podell R. National guidelines for the management of asthma in adults. Am Fam Physician. 1992;46:1189-96.
4. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 1997. NIH publication 97-4051.
5. Doerschug KC, Peterson MW, Dayton CS, Kline JN. Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med. 1999;159:1735-41.
6. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. Bethesda, MD: National Heart, Lung, and Blood Institute; 2002. NIH publication 02-5075.
7. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-tomoderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther. 1997;19:675-90.
8. Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998;102:935-42.
9. Adkins JC, Brogden RN. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs. 1998;55:121-44.
10. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1997;126:177-83.
11. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000;105:1123-29.
12. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther. 2001;23:1589-1600.
13. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999;160:1862-68.
14. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319:87-90.
15. Tonelli M, Zingoni M, Bacci E, et al. Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics. Pulm Pharmacol Ther. 2003;16:237-40.
16. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001;120:423-30.
17. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 1999;103:1075-80.
18. Ollendorf D, Pozniak A, Bowers B, Oster G. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma. Chest. 2000;118(4):185S.
19. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med. 2001;95:83-89.
20. Sheth K, Borker R, Emmett A, et al. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics. 2002;20:909-18.
21. Menendez R, Stanford RH, Edwards L, et al. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics. 2001;19:865-74.
22. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy. 2002;22:166-74.
23. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother. 1998;32:220-32.
24. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
25. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313.
26. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-64.
27. Chen Y, Dales R, Tang M, Krewski D. Obesity may increase the incidence of asthma in women but not in men: longitudinal observations from the Canadian National Population Health Surveys. Am J Epidemiol. 2002;155:198-202.
28. Guerra S, Sherrill DL, Bobadilla A, et al. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. 2002;122:1256-63.
29. Shaheen SO, Sterne JA, Montgomery SM, Azima H. Birth weight, body mass index and asthma in young adults. Thorax. 1999;54:396-402.
30. Kuo A, Craig TJ. A retrospective study of risk factors for repeated admissions for asthma in a rural/suburban university hospital. J Am Osteopath Assoc. 2001;101:S14-S17; quiz S517-S518.
31. Hessel PA, Mitchell I, Tough S, et al. Risk factors for death from asthma. Prairie Provinces Asthma Study Group. Ann Allergy, Asthma Immunol. 1999;83:362-68.
32. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol. 1996;98:1016-18.
33. Perkins SM, Tu W, Underhill MG, Zhou X, Murray MD. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepi Drug Safety. 2000;9:93-101.
34. Drazen JM, Israel E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med. 1998;158:1697-98.
35. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245-51.
36. Reinus JF, Persky S, Burkiewicz JS, et al. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med. 2000;133:964-68.
37. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf. 1999;21:241-51.
38. Sivri A, Coplu L. Effect of the long-term use of inhaled corticosteroids on bone mineral density in asthmatic women. Respirology. 2001;6:131-34.
39. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345:941-47.
40. Tug T, Kamanli A, Tug E. Effects of long-term inhaled steroid use on bone mineral density in asthma patients. J Investig Allergol Clin Immunol. 2001;11:300-02.
41. Elmstahl S, Ekstrom H, Galvard H, Jet al. Is there an association between inhaled corticosteroids and bone density in postmenopausal women? J Allergy Clin Immunol. 2003;111:91-96.
42. Armstrong EP, Malone DC. Fluticasone is associated with lower asthmarelated costs than leukotriene modifiers in a real-world analysis. Pharmacotherapy. 2002;22:1117-23.
43. Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol. 2004;92:523-29.
44. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol. 2002;109:433-39.
45. Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001;107:94-98.
46. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med. 2001;95:227-34.
47. O'Connor RD, O'Donnell JC, Pinto LA, et al. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest. 2002;121:1028-35.
48. Snyder L, Blanc PD, Katz PP, et al. Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? Arch Intern Med. 2004;164:617-22.
49. Schultz A, Stuck BA, Feuring M, et al. Novel approaches in the treatment of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2003;3:21-27.
50. Phipatanakul W, Eggleston PA, Conover-Walker MK, et al. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. J Allergy Clin Immunol. 2000;105: 704-10.
51. Corren J, Spector S, Fuller L, et al. Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol. 2001;87:211-7.
52. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol. 2003;90:182-90; quiz 190-91, 232.
53. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Efficacy supplements approved in calendar year 2002. Available at: http://www.fda.gov/cder/rdmt/ESCY02AP.HTM. Accessed October 6, 2005.
54. Lakomski PG, Chitre M. Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan. J Manag Care Pharm. 2004;10(2):115-21.
55. Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and health care utilization. Ann Pharmacother. 2002;36:557-64.
56. Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-95.
57. Bright R, Avorn J, Everitt D. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol. 1989;42:937-45.